AbsEn.i
Curation
Istex
Racine
Curation
Checkpoint
Istex
Racine
Istex
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Curation (Istex)

Index « AbsEn.i » - entrée « potential »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
potent < potential < potentially  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 78.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000012 (2005) Norihiro Nishimoto [Japon]Clinical studies in patients with Castleman’s disease, Crohn’s disease, and rheumatoid arthritis in Japan
000057 (2007) Peter Taylor [Royaume-Uni]IL‐6 inhibition in the treatment of rheumatoid arthritis
000091 (2012) Sooha Kim [Royaume-Uni] ; Andrew J. K. Östör [Royaume-Uni] ; Muhammad K. Nisar [Royaume-Uni]Interleukin-6 and cytochrome-P450, reason for concern?
000122 (2006) C. Christodoulou [Royaume-Uni] ; E. H. Choy [Royaume-Uni]Joint inflammation and cytokine inhibition in rheumatoid arthritis
000134 (2013) F. Behrens [Allemagne] ; M. Köhm [Allemagne]Personalisierte Medizin bei Zytokin-gerichteten Therapien
000144 (2012) U. Lange [Allemagne] ; U. Müller-Ladner [Allemagne]Potenzielle rheumatologische Medikamentenwechselwirkungen im Alter
000171 (2015) Takashi Yamamura [Japon]Vascular endothelial growth factor: A potential target of therapy in neuromyelitis optica?
000173 (2013) Nam Trung Nguyen [Japon, Viêt Nam] ; Taisuke Nakahama [Japon] ; Tadamitsu Kishimoto [Japon]Aryl hydrocarbon receptor and experimental autoimmune arthritis
000193 (2012) L. K. King ; A. Lee [Australie] ; A. Anandacoomarasamy [Australie]Use of biological disease‐modifying anti‐rheumatic drugs in patients with concurrent rheumatic disease and hepatitis B
000205 (2012) A. Rubbert-Roth [Allemagne] ; H.-F. Petereit [Allemagne]Nebenwirkungen der medikamentösen Therapie rheumatischer Erkrankungen am Nervensystem
000211 (2006) Lyndell Lim [États-Unis] ; Eric B. Suhler [États-Unis] ; Justine R. Smith [États-Unis]Biologic therapies for inflammatory eye disease
000233 (2010) Hiroshi Kato [États-Unis] ; David A. Fox [États-Unis]Are Th17 Cells an Appropriate New Target in the Treatment of Rheumatoid Arthritis?
000234 (2012) G. Lippi [Italie] ; G. Targher [Italie]Optimal therapy for reduction of lipoprotein(a)
000240 (2013) Naoshi Nishina [Japon] ; Yuko Kaneko [Japon] ; Hideto Kameda [Japon] ; Masataka Kuwana [Japon] ; Tsutomu Takeuchi [Japon]Reduction of plasma IL-6 but not TNF-α by methotrexate in patients with early rheumatoid arthritis: a potential biomarker for radiographic progression
000278 (2013) Frédéric Perros [France] ; Marc Humbert [France] ; Sylvia Cohen-Kaminsky [France]Hypertension artérielle pulmonaire
000284 (2012) Usama Elewa [Espagne] ; Maria Dolores Sanchez-Ni O [Espagne] ; Catalina Martin-Cleary [Espagne] ; Beatriz Fernandez-Fernandez [Espagne] ; Jesus Egido [Espagne] ; Alberto Ortiz [Espagne]Cardiovascular risk biomarkers in CKD: the inflammation link and the road less traveled
000296 (2012) Adel Alawadhi [Koweït] ; Khaldoon Alawneh [Jordanie] ; Zeyad Ahmed Alzahrani [Arabie saoudite]The effect of neutralizing antibodies on the sustainable efficacy of biologic therapies: what’s in it for African and Middle Eastern rheumatologists
000300 (2012) Joerg-Patrick Stübgen [États-Unis]Targeted immunotherapy trials for idiopathic inflammatory myopathies
000457 (2013) C. Guillou ; G. Avenel ; C. Derambure ; M. Verdet ; M.-L. Golinski ; M. Hiron ; S. Adriouch ; O. Boyer [France] ; T. Lequerré ; O. VittecoqAB0305 Potential in vitro immunomodulatory effects of the recombinant human alpha-enolase on peripheral blood mononuclear cells (pbmcs) from healthy donors.
000472 (2013) S. Spitz [États-Unis] ; D. Wilkins [États-Unis] ; E. Esfandiari [Royaume-Uni] ; A. Godwood [Royaume-Uni] ; L. Roskos [États-Unis] ; P. Ryan [États-Unis] ; F. Magrini [Royaume-Uni]AB0576 Evaluation of surfactant protein-D and KL-6 as potential pulmonary safety biomarkers during mavrilimumab treatment
000511 (2011) Stefan Kleinert [Allemagne] ; Hans-Peter Tony [Allemagne] ; Andreas Krause [Allemagne] ; Martin Feuchtenberger [Allemagne] ; Siegfried Wassenberg [Allemagne] ; Constanze Richter [Allemagne] ; Ekkehard Röther [Allemagne] ; Wolfgang Spieler [Allemagne] ; Holger Gnann [Allemagne] ; Bianca M. Wittig [Allemagne]Impact of patient and disease characteristics on therapeutic success during adalimumab treatment of patients with rheumatoid arthritis: data from a German noninterventional observational study

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Istex/Curation

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i -k "potential" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Istex/Curation/AbsEn.i  \
                -Sk "potential" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Istex/Curation/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Istex
   |étape=   Curation
   |type=    indexItem
   |index=    AbsEn.i
   |clé=    potential
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021